These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 26345951)
1. Association between ERCC1 and ERCC2 gene polymorphisms and chemotherapy response and overall survival in osteosarcoma. Cao ZH; Yin HP; Jiang N; Yu B Genet Mol Res; 2015 Aug; 14(3):10145-51. PubMed ID: 26345951 [TBL] [Abstract][Full Text] [Related]
2. Investigation of ERCC1 and ERCC2 gene polymorphisms and response to chemotherapy and overall survival in osteosarcoma. Zhang Q; Lv LY; Li BJ; Zhang J; Wei F Genet Mol Res; 2015 Sep; 14(3):11235-41. PubMed ID: 26400354 [TBL] [Abstract][Full Text] [Related]
3. Genetic polymorphisms in nucleotide excision repair pathway influences response to chemotherapy and overall survival in osteosarcoma. Sun Y; Wu Y; Li W; Kong Z; Zou X Int J Clin Exp Pathol; 2015; 8(7):7905-12. PubMed ID: 26339355 [TBL] [Abstract][Full Text] [Related]
4. The effect of ERCC1 and ERCC2 gene polymorphysims on response to cisplatin based therapy in osteosarcoma patients. Obiedat H; Alrabadi N; Sultan E; Al Shatti M; Zihlif M BMC Med Genet; 2018 Jul; 19(1):112. PubMed ID: 29980176 [TBL] [Abstract][Full Text] [Related]
5. Investigation on the DNA repaired gene polymorphisms and response to chemotherapy and overall survival of osteosarcoma. Ji WP; He NB Int J Clin Exp Pathol; 2015; 8(1):894-9. PubMed ID: 25755792 [TBL] [Abstract][Full Text] [Related]
6. Prognostic value of ERCC1 and ERCC2 gene polymorphisms in patients with gastric cancer receiving platinum-based chemotherapy. Mo J; Luo M; Cui J; Zhou S Int J Clin Exp Pathol; 2015; 8(11):15065-71. PubMed ID: 26823845 [TBL] [Abstract][Full Text] [Related]
7. Genetic variability of DNA repair mechanisms influences chemotherapy outcome of gastric cancer. Yu H; Wu X; Zhang Y; Jin Z; Li G; Zhao H Int J Clin Exp Pathol; 2015; 8(4):4106-12. PubMed ID: 26097599 [TBL] [Abstract][Full Text] [Related]
8. Genetic polymorphisms of DNA repair pathways influence the response to chemotherapy and overall survival of gastric cancer. Zhou J; Liu ZY; Li CB; Gao S; Ding LH; Wu XL; Wang ZY Tumour Biol; 2015 Apr; 36(4):3017-23. PubMed ID: 25542228 [TBL] [Abstract][Full Text] [Related]
9. Genetic polymorphisms in ERCC1 and ERCC2 genes are associated with response to chemotherapy in osteosarcoma patients among Chinese population: a meta-analysis. Zhang H; Ge J; Hong H; Bi L; Sun Z World J Surg Oncol; 2017 Apr; 15(1):75. PubMed ID: 28388903 [TBL] [Abstract][Full Text] [Related]
10. Genetic variability of genes involved in DNA repair influence treatment outcome in osteosarcoma. Wang MJ; Zhu Y; Guo XJ; Tian ZZ Genet Mol Res; 2015 Sep; 14(3):11652-7. PubMed ID: 26436406 [TBL] [Abstract][Full Text] [Related]
11. Influence of ERCC2 gene polymorphisms on the treatment outcome of osteosarcoma. Liu ZF; Asila AL; Aikenmu K; Zhao J; Meng QC; Fang R Genet Mol Res; 2015 Oct; 14(4):12967-72. PubMed ID: 26505449 [TBL] [Abstract][Full Text] [Related]
12. Genetic variability of genes in NER pathway influences the treatment outcome of gastric cancer. Xue MH; Li GY; Wu XJ; Zhang CX; Zhang CF; Zhu KX Int J Clin Exp Pathol; 2015; 8(5):5563-9. PubMed ID: 26191265 [TBL] [Abstract][Full Text] [Related]
13. Association of four ERCC1 and ERCC2 SNPs with survival of bone tumour patients. Hao T; Feng W; Zhang J; Sun YJ; Wang G Asian Pac J Cancer Prev; 2012; 13(8):3821-4. PubMed ID: 23098477 [TBL] [Abstract][Full Text] [Related]
14. Association of single nucleotide polymorphisms of DNA repair genes in NER pathway and susceptibility to pancreatic cancer. Zhao F; Shang Y; Zeng C; Gao D; Li K Int J Clin Exp Pathol; 2015; 8(9):11579-86. PubMed ID: 26617894 [TBL] [Abstract][Full Text] [Related]
15. Association of ERCC gene polymorphism with osteosarcoma risk. Wang G; Li J; Xu X; Gupta RK; Gao X Afr Health Sci; 2020 Dec; 20(4):1840-1848. PubMed ID: 34394247 [TBL] [Abstract][Full Text] [Related]
16. Genetic variability of ERCC1 and ERCC2 influences treatment outcomes in gastric cancer. Yu WH; Wang YX; Guo JQ; Wang YL; Zheng JS; Zhu KX Genet Mol Res; 2015 Dec; 14(4):17529-35. PubMed ID: 26782397 [TBL] [Abstract][Full Text] [Related]
17. Genetic variability of ERCC1 and ERCC2 genes involved in the nucleotide excision repair pathway influences the treatment outcome of gastric cancer. Zheng DL; Tang GD; Chen YN; Zhang T; Qin MB Genet Mol Res; 2016 Apr; 15(2):. PubMed ID: 27173253 [TBL] [Abstract][Full Text] [Related]
18. Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients. Caronia D; Patiño-García A; Milne RL; Zalacain-Díez M; Pita G; Alonso MR; Moreno LT; Sierrasesumaga-Ariznabarreta L; Benítez J; González-Neira A Pharmacogenomics J; 2009 Oct; 9(5):347-53. PubMed ID: 19434073 [TBL] [Abstract][Full Text] [Related]
19. Polymorphisms in ERCC1 and XPF gene and response to chemotherapy and overall survival of non-small cell lung cancer. Shi ZH; Shi GY; Liu LG Int J Clin Exp Pathol; 2015; 8(3):3132-7. PubMed ID: 26045829 [TBL] [Abstract][Full Text] [Related]
20. ERCC polymorphisms and risk of osteosarcoma: a meta-analysis. Chen XJ; Tong ZC; Kang X; Wang ZC; Huang GL; Yang TM; Dong L Eur Rev Med Pharmacol Sci; 2018 Oct; 22(20):6658-6666. PubMed ID: 30402838 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]